Associations - Kadcyla (ado-trastuzumab emtansine)

HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	ado-trastuzumab emtansine Sensitive: A1 - Approval ado-trastuzumab emtansine Sensitive : A1	ado-trastuzumab emtansine Sensitive: A1 - Approval ado-trastuzumab emtansine Sensitive : A1
HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	ado-trastuzumab emtansine Sensitive: A2 - Guideline ado-trastuzumab emtansine Sensitive : A2	ado-trastuzumab emtansine Sensitive: A2 - Guideline ado-trastuzumab emtansine Sensitive : A2
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	pertuzumab + ado-trastuzumab emtansine Sensitive: B - Late Trials pertuzumab + ado-trastuzumab emtansine Sensitive : B	pertuzumab + ado-trastuzumab emtansine Sensitive: B - Late Trials pertuzumab + ado-trastuzumab emtansine Sensitive : B
ERBB3 expression	HER2 Positive Breast Cancer	ERBB3 expression	HER2 Positive Breast Cancer	ado-trastuzumab emtansine Sensitive: B - Late Trials ado-trastuzumab emtansine Sensitive : B	ado-trastuzumab emtansine Sensitive: B - Late Trials ado-trastuzumab emtansine Sensitive : B
PTEN expression	HER2 Positive Breast Cancer	PTEN expression	HER2 Positive Breast Cancer	ado-trastuzumab emtansine Resistant: B - Late Trials ado-trastuzumab emtansine Resistant : B	ado-trastuzumab emtansine Resistant: B - Late Trials ado-trastuzumab emtansine Resistant : B
EGFR expression	HER2 Positive Breast Cancer	EGFR expression	HER2 Positive Breast Cancer	ado-trastuzumab emtansine Sensitive: B - Late Trials ado-trastuzumab emtansine Sensitive : B	ado-trastuzumab emtansine Sensitive: B - Late Trials ado-trastuzumab emtansine Sensitive : B
PIK3CA K111N	Breast Cancer	PIK3CA K111N	Breast Cancer	ado-trastuzumab emtansine Sensitive: B - Late Trials ado-trastuzumab emtansine Sensitive : B	ado-trastuzumab emtansine Sensitive: B - Late Trials ado-trastuzumab emtansine Sensitive : B
RAB5A expression	Breast Cancer	RAB5A expression	Breast Cancer	ado-trastuzumab emtansine Sensitive: B - Late Trials ado-trastuzumab emtansine Sensitive : B	ado-trastuzumab emtansine Sensitive: B - Late Trials ado-trastuzumab emtansine Sensitive : B
PIK3CA mutation	HER2 Positive Breast Cancer	PIK3CA mutation	HER2 Positive Breast Cancer	pertuzumab + ado-trastuzumab emtansine Resistant: B - Late Trials pertuzumab + ado-trastuzumab emtansine Resistant : B	pertuzumab + ado-trastuzumab emtansine Resistant: B - Late Trials pertuzumab + ado-trastuzumab emtansine Resistant : B
HER-2 expression	HER2 Positive Breast Cancer	HER-2 expression	HER2 Positive Breast Cancer	pertuzumab + ado-trastuzumab emtansine Sensitive: B - Late Trials pertuzumab + ado-trastuzumab emtansine Sensitive : B	pertuzumab + ado-trastuzumab emtansine Sensitive: B - Late Trials pertuzumab + ado-trastuzumab emtansine Sensitive : B
HER-2 amplification	HER2 Positive Breast Cancer	HER-2 amplification	HER2 Positive Breast Cancer	pertuzumab + ado-trastuzumab emtansine Sensitive: B - Late Trials pertuzumab + ado-trastuzumab emtansine Sensitive : B	pertuzumab + ado-trastuzumab emtansine Sensitive: B - Late Trials pertuzumab + ado-trastuzumab emtansine Sensitive : B
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	ado-trastuzumab emtansine + tucatinib Sensitive: B - Late Trials ado-trastuzumab emtansine + tucatinib Sensitive : B	ado-trastuzumab emtansine + tucatinib Sensitive: B - Late Trials ado-trastuzumab emtansine + tucatinib Sensitive : B
HER-2 positive	Colon Cancer	HER-2 positive	Colon Cancer	ado-trastuzumab emtansine Sensitive: C1 - Off-label ado-trastuzumab emtansine Sensitive : C1	ado-trastuzumab emtansine Sensitive: C1 - Off-label ado-trastuzumab emtansine Sensitive : C1
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	ado-trastuzumab emtansine Sensitive: C1 - Off-label ado-trastuzumab emtansine Sensitive : C1	ado-trastuzumab emtansine Sensitive: C1 - Off-label ado-trastuzumab emtansine Sensitive : C1
HER-2 positive	Pancreatic Cancer	HER-2 positive	Pancreatic Cancer	ado-trastuzumab emtansine Sensitive: C1 - Off-label ado-trastuzumab emtansine Sensitive : C1	ado-trastuzumab emtansine Sensitive: C1 - Off-label ado-trastuzumab emtansine Sensitive : C1
HER-2 positive	Bladder Cancer	HER-2 positive	Bladder Cancer	ado-trastuzumab emtansine Sensitive: C1 - Off-label ado-trastuzumab emtansine Sensitive : C1	ado-trastuzumab emtansine Sensitive: C1 - Off-label ado-trastuzumab emtansine Sensitive : C1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	neratinib + ado-trastuzumab emtansine Sensitive: C2 – Inclusion Criteria neratinib + ado-trastuzumab emtansine Sensitive : C2	neratinib + ado-trastuzumab emtansine Sensitive: C2 – Inclusion Criteria neratinib + ado-trastuzumab emtansine Sensitive : C2
HER-2 overexpression	HER2 Positive Breast Cancer	HER-2 overexpression	HER2 Positive Breast Cancer	ado-trastuzumab emtansine Sensitive: C2 – Inclusion Criteria ado-trastuzumab emtansine Sensitive : C2	ado-trastuzumab emtansine Sensitive: C2 – Inclusion Criteria ado-trastuzumab emtansine Sensitive : C2
HER-2 amplification	HER2 Positive Breast Cancer	HER-2 amplification	HER2 Positive Breast Cancer	neratinib + ado-trastuzumab emtansine Sensitive: C2 – Inclusion Criteria neratinib + ado-trastuzumab emtansine Sensitive : C2	neratinib + ado-trastuzumab emtansine Sensitive: C2 – Inclusion Criteria neratinib + ado-trastuzumab emtansine Sensitive : C2
HER-2 amplification	Salivary Gland Cancer	HER-2 amplification	Salivary Gland Cancer	ado-trastuzumab emtansine Sensitive: C2 – Inclusion Criteria ado-trastuzumab emtansine Sensitive : C2	ado-trastuzumab emtansine Sensitive: C2 – Inclusion Criteria ado-trastuzumab emtansine Sensitive : C2
HER-2 amplification	Endometrial Cancer	HER-2 amplification	Endometrial Cancer	ado-trastuzumab emtansine Sensitive: C2 – Inclusion Criteria ado-trastuzumab emtansine Sensitive : C2	ado-trastuzumab emtansine Sensitive: C2 – Inclusion Criteria ado-trastuzumab emtansine Sensitive : C2
HER-2 amplification	Lung Cancer	HER-2 amplification	Lung Cancer	ado-trastuzumab emtansine Sensitive: C2 – Inclusion Criteria ado-trastuzumab emtansine Sensitive : C2	ado-trastuzumab emtansine Sensitive: C2 – Inclusion Criteria ado-trastuzumab emtansine Sensitive : C2
HER-2 amplification	Gastroesophageal Junction Adenocarcinoma	HER-2 amplification	Gastroesophageal Junction Adenocarcinoma	ado-trastuzumab emtansine Sensitive: C2 – Inclusion Criteria ado-trastuzumab emtansine Sensitive : C2	ado-trastuzumab emtansine Sensitive: C2 – Inclusion Criteria ado-trastuzumab emtansine Sensitive : C2
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	palbociclib + ado-trastuzumab emtansine Sensitive: C2 – Inclusion Criteria palbociclib + ado-trastuzumab emtansine Sensitive : C2	palbociclib + ado-trastuzumab emtansine Sensitive: C2 – Inclusion Criteria palbociclib + ado-trastuzumab emtansine Sensitive : C2
HER-2 overexpression	HER2 Positive Breast Cancer	HER-2 overexpression	HER2 Positive Breast Cancer	ado-trastuzumab emtansine Sensitive: C2 – Inclusion Criteria ado-trastuzumab emtansine Sensitive : C2	ado-trastuzumab emtansine Sensitive: C2 – Inclusion Criteria ado-trastuzumab emtansine Sensitive : C2
HER-2 overexpression	Breast Cancer	HER-2 overexpression	Breast Cancer	ado-trastuzumab emtansine Sensitive: C2 – Inclusion Criteria ado-trastuzumab emtansine Sensitive : C2	ado-trastuzumab emtansine Sensitive: C2 – Inclusion Criteria ado-trastuzumab emtansine Sensitive : C2
HER-2 underexpression	Breast Cancer	HER-2 underexpression	Breast Cancer	ado-trastuzumab emtansine Sensitive: C2 – Inclusion Criteria ado-trastuzumab emtansine Sensitive : C2	ado-trastuzumab emtansine Sensitive: C2 – Inclusion Criteria ado-trastuzumab emtansine Sensitive : C2
HER-2 expression	HER2 Positive Breast Cancer	HER-2 expression	HER2 Positive Breast Cancer	ado-trastuzumab emtansine Sensitive: C3 – Early Trials ado-trastuzumab emtansine Sensitive : C3	ado-trastuzumab emtansine Sensitive: C3 – Early Trials ado-trastuzumab emtansine Sensitive : C3
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	atezolizumab + ado-trastuzumab emtansine Resistant: C3 – Early Trials atezolizumab + ado-trastuzumab emtansine Resistant : C3	atezolizumab + ado-trastuzumab emtansine Resistant: C3 – Early Trials atezolizumab + ado-trastuzumab emtansine Resistant : C3
HER-2 underexpression	Lung Adenocarcinoma	HER-2 underexpression	Lung Adenocarcinoma	ado-trastuzumab emtansine Sensitive: C3 – Early Trials ado-trastuzumab emtansine Sensitive : C3	ado-trastuzumab emtansine Sensitive: C3 – Early Trials ado-trastuzumab emtansine Sensitive : C3
HER-2 exon 20 insertion	Lung Adenocarcinoma	HER-2 exon 20 insertion	Lung Adenocarcinoma	ado-trastuzumab emtansine Sensitive: C3 – Early Trials ado-trastuzumab emtansine Sensitive : C3	ado-trastuzumab emtansine Sensitive: C3 – Early Trials ado-trastuzumab emtansine Sensitive : C3
HER-2 mutation	Lung Adenocarcinoma	HER-2 mutation	Lung Adenocarcinoma	ado-trastuzumab emtansine Sensitive: C3 – Early Trials ado-trastuzumab emtansine Sensitive : C3	ado-trastuzumab emtansine Sensitive: C3 – Early Trials ado-trastuzumab emtansine Sensitive : C3

Kadcyla (ado-trastuzumab emtansine)

Associations
(97)

Associations
(97)

Kadcyla (ado-trastuzumab emtansine)

Associations(97)

Associations(97)

Associations
(97)

Associations
(97)